Clinical trial
Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot…
NCT00119249 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00119249 |
|---|---|
| Title | Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery |
| Official title | A Phase II Study of BAY 43-9006 (NSC 724772) in Unresectable Stage III and IV Melanoma (IND 69,869) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage III Melanoma, Stage IV Melanoma |
| Intervention type | Drug, Other |
| Interventions | sorafenib tosylate, laboratory biomarker analysis |
| Enrollment | 74 |
| Start date | Jun 1, 2005 |
| Primary completion | Nov 1, 2007 |
| First posted | Jul 13, 2005 |
| Last update posted | Jan 15, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: